3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?
| Autor: | Grazia Chiellini, Lavinia Bandini, Simona Sestito, Grazia Rutigliano |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
obesity 3-iodothyronamine 030209 endocrinology & metabolism Review Biology thyronamine-like analogs Catalysis Energy homeostasis metabolic syndrome Receptors G-Protein-Coupled lcsh:Chemistry Inorganic Chemistry 3-Iodothyronamine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine TAAR1 Thyronines medicine Animals Humans Physical and Theoretical Chemistry Receptor lcsh:QH301-705.5 Molecular Biology Spectroscopy trace amine-associated receptor 1 (TAAR1) neurodegenerative disorders Organic Chemistry Neurodegenerative Diseases General Medicine medicine.disease Computer Science Applications 030104 developmental biology lcsh:Biology (General) lcsh:QD1-999 chemistry Antiobesity drugs Molecular targets Metabolic syndrome Energy Metabolism Neuroscience Hormone |
| Zdroj: | International Journal of Molecular Sciences International Journal of Molecular Sciences, Vol 21, Iss 6, p 2005 (2020) |
| Popis: | In the two decades since its discovery, a large body of evidence has amassed to highlight the potential of 3-iodothyronamine (T1AM) as an antiobesity drug, whose pleiotropic signaling actions profoundly impact energy metabolism. In the present review, we recapitulate the most relevant properties of T1AM, including its structural and functional relationship to thyroid hormone, its endogenous levels, molecular targets, as well as its genomic and non-genomic effects on metabolism elicited in experimental models after exogenous administration. The physiological and pathophysiological relevance of T1AM in the regulation of energy homeostasis and metabolism is also discussed, along with its potential therapeutic applications in metabolic disturbances. Finally, we examine a number of T1AM analogs that have been recently developed with the aim of designing novel pharmacological agents for the treatment of interlinked diseases, such as metabolic and neurodegenerative disorders, as well as additional synthetic tools that can be exploited to further explore T1AM-dependent mechanisms and the physiological roles of trace amine-associated receptor 1 (TAAR1)-mediated effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|